Zanidatamab + chemotherapy ± tislelizumab for first-line HER2-positive locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma: Primary analysis from HERIZON-GEA-01

In this OncLive Rapid Readout, Elena Elimova, MD, MSc, provides an expert overview of the primary analysis from the HERIZON-GEA-01 trial, presented at the ASCO Gastrointestinal Cancers Symposium. The discussion focuses on the efficacy and safety of zanidatamab combined with chemotherapy, with or without the PD-1 inhibitor tislelizumab, as first-line treatment for patients with HER2-positive locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma. Dr Elimova reviews key study design elements, patient population characteristics, and clinically meaningful outcomes, including response rates and progression-free survival signals, while contextualizing the data within the evolving HER2-directed treatment landscape. She also addresses safety considerations and the potential implications of dual HER2 targeting with or without immunotherapy for routine clinical practice. This concise expert analysis highlights how emerging data from HERIZON-GEA-01 may inform treatment decision-making and future research directions in HER2-positive gastroesophageal cancer.